checkAd
    Startseite > Aktien > Monopar Therapeutics > Nachrichten
    Monopar Therapeutics Aktie
    0,6300
     
    EUR
    -7,35 %
    -0,0500 EUR
    Letzter Kurs 10.05.24 Tradegate
    0,6100
     
    EUR
    3.287 STK
    Geldkurs 08:00:21
    0,6350
     
    EUR
    3.126 STK
    Briefkurs 08:00:21
    ISIN: US61023L1089 · WKN: A2PQNF · SYM: 1IY · USA

    Neueste Nachrichten

    Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
    09.05.24 · globenewswire · Monopar Therapeutics
    Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
    18.04.24 · globenewswire · Monopar Therapeutics
    Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
    16.04.24 · globenewswire · Monopar Therapeutics
    Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
    10.04.24 · globenewswire · Monopar Therapeutics
    Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
    28.03.24 · globenewswire · Monopar Therapeutics
    Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
    05.03.24 · globenewswire · Monopar Therapeutics
    Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
    27.02.24 · globenewswire · Monopar Therapeutics
    Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
    22.02.24 · globenewswire · Monopar Therapeutics
    Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
    20.02.24 · globenewswire · Monopar Therapeutics
    Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
    09.11.23 · globenewswire · Monopar Therapeutics
    Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
    01.11.23 · globenewswire · Monopar Therapeutics
    Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
    10.10.23 · globenewswire · Monopar Therapeutics